Search Results: 100% Pass Quiz High Pass-Rate Juniper - JN0-281 - Data Center, Associate (JNCIA-DC) New Braindumps Ebook 🐍 Open ➽ www.pdfvce.com 🢪 enter ➡ JN0-281 ️⬅️ and obtain a free download 🔮Valid Exam JN0-281 Book
The study reveals replication stress in ecDNA enabled cancers as a unique vulnerability and therapeutic strategy for treating gene amplified cancers Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today will present a new finding at the American…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that patients from the INNATE Phase 2 trial in the ovarian cancer combination cohort with platinum resistant ovarian cancer…
Read More
Excerpt from the Press Release: DURHAM, NC, USA I January 8, 2021 I Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has acquired Oncoceutics, Inc., a privately-held, clinical-stage biotechnology company developing imipridones, a novel class of compounds. Oncoceutics’ lead…
Read More
Primary endpoint in Intention to Treat (ITT) was not met despite large absolute reductions in Systolic Blood Pressure (SBP) 12.6 mmHg placebo-adjusted reduction in SBP with 2 mg baxdrostat in a pre-specified subgroup that represents approximately 81-89% of the U.S. hypertension population (nominal p-value = 0.001) Safety profile and tolerability consistent with BrigHtn Phase 2…
Read More
Randomized Phase 2 clinical study evaluating SRF388 in first-line hepatocellular carcinoma in clinical collaboration with Roche Single-arm Phase 2 clinical study evaluating SRF388 as a monotherapy in patients with previously-treated non-small-cell lung cancer Excerpt from the Press Release: CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies…
Read More
Durable responses achieved in highly refractory patients as monotherapy (one patient with relapsed squamous cell lung cancer) and in combination with pembrolizumab (several subjects with relapsed squamous cell carcinoma of the anal canal and head and neck squamous cell carcinoma) Dose escalation portion of the study has completed and recommended dose declared, as monotherapy and…
Read More
Excerpt from the Press Release: LEXINGTON, Mass., Aug. 26, 2021 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that results from a global Phase 2 clinical study of balstilimab monotherapy in…
Read More
Excerpt from the Press Release: Philadelphia, PA, November 4, 2021 – Spirovant Sciences, a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF), today presented SP-101, an investigational novel recombinant adeno-associated virus (AAV) gene therapy selected for its tropism to human airway epithelia, at the 2021 North American Cystic Fibrosis Conference (NACFC 2021).…
Read MoreHow Does TrialStat Compare To Other EDC Platforms? Book Your Demo Today To Learn More. Selecting an eClinical Solution shouldn’t involve guesswork or crossed fingers. Can your EDC provider clearly demonstrate what differentiates them in the crowded eClinical technology marketplace? We can. Compared to other EDC solutions on the market, TrialStat is a leader in…
Read More
Study conducted with investigators at Dana-Farber Cancer Institute showed ctDNA changes pre- and post-ICI therapy associated with resistance to treatment; Suggests liquid biopsy may be a useful tool for personalizing immunotherapy in patients with metastatic urothelial carcinoma Excerpt from the Press Release: PALO ALTO, Calif.–(BUSINESS WIRE)–Precision oncology company Lucence, in collaboration with researchers at Dana-Farber…
Read More